Wegovy users keep weight off for four years, Novo Nordisk study says
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and governments to cover the cost of the effective but expensive drug.
Weight loss from Wegovy sustained for up to four years, trial shows
A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and three months—but then hit a plateau or "set point." But that early weight loss was generally maintained for up to four years while people continued taking the weekly injections.
The data was presented Tuesday at the European Congress on Obesity in Italy. As CNN ...
Blockbuster weight-loss drug Wegovy could bankrupt the U.S. health care system unless the price drops, according to a staff ...
Senator Bernie Sanders is upping the pressure on Danish drugmaker Novo Nordisk A/S to lower the cost of its blockbuster ...
New research suggests that slowly tapering off GLP-1 drugs like Ozempic and Wegovy while adopting lifestyle changes may help ...
New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps ...
Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish ...
Dustin Gee lost over 50 pounds since he began taking Wegovy in 2023. Here’s how he’s preparing to avoid rebound weight gain ...
News Nation on MSN1d
Wegovy may help with heart issues: AnalysisResults showed that patients lost an average of nearly 10% of their total body weight after 65 weeks on Wegovy.
The results of the longest-running trial of semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, are here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results